Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma

References

• Forastiere AA. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol 1994; 211(5 Suppl l2)20–7
   Google Scholar
• Brown SM, MacLean AR, Aitken JD, Harland J. ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro. Gen Virol 1994; 75(Pt 12)3679–86
   PubMed Web of Science ®Google Scholar
• Dolan A, McKie E, MacLean AR, McGeoch DJ. Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17. J Gen Virol 1992; 73: 971–3
   PubMed Web of Science ®Google Scholar
• Ackermann M, Chou J, Sarmiento M, Lerner RA, Roizman B. Identification by antibody to a synthetic peptide of a protein specified by a diploid gene located in the terminal repeats of the L component of herpes simplex virus genome. J Virol 1986; 58: 843–50
   PubMed Web of Science ®Google Scholar
• Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938–43
   PubMed Web of Science ®Google Scholar
• Lasner TM, Kesari S, Brown SM, Lee VM, Fraser NW, Trojanowski JQ. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J Neuropathol Exp Neurol 1996; 55: 1259–69
   PubMed Web of Science ®Google Scholar
• Randazzo BP, Kesari S, Gesser RM, Alsop D, Ford JC, Brown SM, et al. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 1995; 211: 94–101
   PubMed Web of Science ®Google Scholar
• Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Investig Dermatol 1997; 108: 933–7
   PubMed Web of Science ®Google Scholar
• Kesari S, Randazzo BP, Valyi-Nagy T, Huang QS, Brown SM, et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 1995; 73: 636–48
   PubMed Web of Science ®Google Scholar
• Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, et al. Use of a “replication-restricted” herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997; 57: 466–71
   PubMed Web of Science ®Google Scholar
• Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999; 10: 3013–29
   PubMed Web of Science ®Google Scholar
• Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859–66
   PubMed Web of Science ®Google Scholar
• Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002; 9: 398–406
   PubMed Web of Science ®Google Scholar
• Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004; 11: 1648–58
   PubMed Web of Science ®Google Scholar
• MacPherson I, Stoker MG. Polyoma transformation of hamster cell clones: an investigation of genetic factors affecting cell competence. Virology 1962; 16: 147–51
   PubMed Web of Science ®Google Scholar
• Todaro GJ, Green H. Quantitative studies of mouse embryo cells in culture and their development into established lines. J Cell Biol 1963; 17: 299–313
   PubMed Web of Science ®Google Scholar
• Brown SM, Ritchie DA, Subak-Sharpe JH. Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. J Gen Virol 1973; 18: 329–46
   PubMed Web of Science ®Google Scholar
• Kano Y, Ohnuma T, Okano T, Holland JF. Effects of vincristine in combination with methotrexate and other anti-tumour agents in human acute lymphoblastic leukaemia cells in culture. Cancer Res 1988; 48: 351–6
   PubMed Web of Science ®Google Scholar
• Steel GG, Peckham MJ. Exploitable mechanisms in combined radio-therapy chemotherapy: the concept of additivity. Int J Radiat Oncol 1979; 5: 85–91
   PubMed Web of Science ®Google Scholar
• Welters MJ, Fichtinger-Schepman AM, Baan RA, Hermsen MA, van der Vijgh WJ, Cloos J, et al. Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int J Cancer 1997; 71: 410–15
   PubMed Web of Science ®Google Scholar
• Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798–80
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60: 6359–66
   PubMed Web of Science ®Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–85
   PubMed Web of Science ®Google Scholar
• MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357: 525–6
   PubMed Web of Science ®Google Scholar
• Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 1999; 10: 1599–606
   PubMed Web of Science ®Google Scholar
• Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1: 162–9
   PubMedGoogle Scholar
• Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001; 193: 12–21
   PubMed Web of Science ®Google Scholar